Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'll talk about it with you. INTT my second biggets holding.
Which others do you like now.
In RAS:NYSE, DOUBLED last earnings run, they moved up earnings date to July 23. RAS benefits fron settling debts on pennies on the dollar no brainer REIT play.
Apr 30, 2010 4.33 4.75 3.99 4.06 10,263,100 4.06
Apr 29, 2010 3.68 4.28 3.51 4.27 14,716,600 4.27
Apr 28, 2010 3.09 3.18 3.00 3.15 2,212,100 3.15
Apr 27, 2010 3.23 3.25 2.95 3.05 3,142,900 3.05
Apr 26, 2010 3.13 3.35 3.08 3.21 4,435,700 3.21
Apr 23, 2010 3.13 3.29 2.91 2.97 6,061,600 2.97
Apr 22, 2010 2.70 3.15 2.60 3.05 7,921,700 3.05
Apr 21, 2010 2.54 2.74 2.54 2.67 4,095,000 2.67
Apr 20, 2010 2.43 2.56 2.39 2.53 1,928,000 2.53
Apr 19, 2010 2.39 2.45 2.33 2.39 2,215,700 2.39
In RAS:NYSE, DOUBLED last earnings run, they moved up earnings date to July 23. RAS benefits fron settling debts on pennies on the dollar no brainer REIT play.
Apr 30, 2010 4.33 4.75 3.99 4.06 10,263,100 4.06
Apr 29, 2010 3.68 4.28 3.51 4.27 14,716,600 4.27
Apr 28, 2010 3.09 3.18 3.00 3.15 2,212,100 3.15
Apr 27, 2010 3.23 3.25 2.95 3.05 3,142,900 3.05
Apr 26, 2010 3.13 3.35 3.08 3.21 4,435,700 3.21
Apr 23, 2010 3.13 3.29 2.91 2.97 6,061,600 2.97
Apr 22, 2010 2.70 3.15 2.60 3.05 7,921,700 3.05
Apr 21, 2010 2.54 2.74 2.54 2.67 4,095,000 2.67
Apr 20, 2010 2.43 2.56 2.39 2.53 1,928,000 2.53
Apr 19, 2010 2.39 2.45 2.33 2.39 2,215,700 2.39
SMTX:NASDAQ 3 Forward PE Ratio
SMTX:NASDAQ ($2.80) announced $.14 EPS in Q1 2010. The CEO said Q2 sales will ramp up further, IMPLYING POTENTIAL $.20 EPS.
SMTX HAS THE POTENTIAL TO EARN $.80 - $1.00 FOR ALL 2010.
SMTX trades at a P/S ratio of 0.20 compared to the Industry average of 0.63. If SMTX traded at even HALF the sector average it would be $5.
The EMS sector is BOOMING driven by computer upgrades induced by Windows 7. IEC, CLS, SANM have posted best results in years, and ahve risen 500%. JBL just had a blowout quarter and forecasts sales will continue accelerating:
http://finance.yahoo.com/news/Jabil-Resu...
The SMTX CEO, John Caldwell, is a corporate turnaround legend. He turned computer company GEAC computer around, it rose from $1 to $11 and was bought out.
The 2 most successful U.S. hedge funds- Bain Capital and Renaissance Capital, own SMTX. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
SMTX has slashed costs to the bone by closing its Boston plant. They will now be able to grow revenues and more importantly, MARGINS, with the cheap labor pool in the China and Mexico. I expect when SMTX hits $70 MM sales again it will have MUCH higher margins and could earn $.30 per share.
SMTX has a tightly held 12 Million float. It can move very fast, in 2005 went from $1 to over $3.50 in a few weeks. It was $8 in 2006.
In short, SMTX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 12 MM share float
- $340 MM market cap
- $250 MM + revenues
- Last CC: Healthy increase in backlog. Customers, new and old, expected to ramp up production in 2010.
- Current quarter: Revenues and net income will be go up this quarter. Profits should approach $.20 per share.
- Traded at $8+ two years ag.o
- Major players in sector (FLEX, JBL, SANM) have gained up to 500% in 2009 while SMTX is still under the radar.
- Frequently mentioned as acquisition candidate because of heavy industry consolidation.
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.
SMTX:NASDAQ 3 Forward PE Ratio
SMTX:NASDAQ ($2.80) announced $.14 EPS in Q1 2010. The CEO said Q2 sales will ramp up further, IMPLYING POTENTIAL $.20 EPS.
SMTX HAS THE POTENTIAL TO EARN $.80 - $1.00 FOR ALL 2010.
SMTX trades at a P/S ratio of 0.20 compared to the Industry average of 0.63. If SMTX traded at even HALF the sector average it would be $5.
The EMS sector is BOOMING driven by computer upgrades induced by Windows 7. IEC, CLS, SANM have posted best results in years, and ahve risen 500%. JBL just had a blowout quarter and forecasts sales will continue accelerating:
http://finance.yahoo.com/news/Jabil-Resu...
The SMTX CEO, John Caldwell, is a corporate turnaround legend. He turned computer company GEAC computer around, it rose from $1 to $11 and was bought out.
The 2 most successful U.S. hedge funds- Bain Capital and Renaissance Capital, own SMTX. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
SMTX has slashed costs to the bone by closing its Boston plant. They will now be able to grow revenues and more importantly, MARGINS, with the cheap labor pool in the China and Mexico. I expect when SMTX hits $70 MM sales again it will have MUCH higher margins and could earn $.30 per share.
SMTX has a tightly held 12 Million float. It can move very fast, in 2005 went from $1 to over $3.50 in a few weeks. It was $8 in 2006.
In short, SMTX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 12 MM share float
- $340 MM market cap
- $250 MM + revenues
- Last CC: Healthy increase in backlog. Customers, new and old, expected to ramp up production in 2010.
- Current quarter: Revenues and net income will be go up this quarter. Profits should approach $.20 per share.
- Traded at $8+ two years ag.o
- Major players in sector (FLEX, JBL, SANM) have gained up to 500% in 2009 while SMTX is still under the radar.
- Frequently mentioned as acquisition candidate because of heavy industry consolidation.
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.
SMTX:NASDAQ 3 Forward PE Ratio
SMTX:NASDAQ ($2.80) announced $.14 EPS in Q4 2009. The CEO said Q2 sales will ramp up further, IMPLYING POTENTIAL $.20 EPS.
SMTX HAS THE POTENTIAL TO EARN $.80 - $1.00 FOR ALL 2010.
SMTX trades at a P/S ratio of 0.20 compared to the Industry average of 0.63. If SMTX traded at even HALF the sector average it would be $5.
The EMS sector is BOOMING driven by computer upgrades induced by Windows 7. IEC, CLS, SANM have posted best results in years, and ahve risen 500%. JBL just had a blowout quarter and forecasts sales will continue accelerating:
http://finance.yahoo.com/news/Jabil-Resu...
The SMTX CEO, John Caldwell, is a corporate turnaround legend. He turned computer company GEAC computer around, it rose from $1 to $11 and was bought out.
The 2 most successful U.S. hedge funds- Bain Capital and Renaissance Capital, own SMTX. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
SMTX has slashed costs to the bone by closing its Boston plant. They will now be able to grow revenues and more importantly, MARGINS, with the cheap labor pool in the China and Mexico. I expect when SMTX hits $70 MM sales again it will have MUCH higher margins and could earn $.30 per share.
SMTX has a tightly held 12 Million float. It can move very fast, in 2005 went from $1 to over $3.50 in a few weeks. It was $8 in 2006.
In short, SMTX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 12 MM share float
- $340 MM market cap
- $250 MM + revenues
- Last CC: Healthy increase in backlog. Customers, new and old, expected to ramp up production in 2010.
- Current quarter: Revenues and net income will be go up this quarter. Profits should approach $.20 per share.
- Traded at $8+ two years ag.o
- Major players in sector (FLEX, JBL, SANM) have gained up to 500% in 2009 while SMTX is still under the radar.
- Frequently mentioned as acquisition candidate because of heavy industry consolidation.
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.
SSN:AMEX $.73 $70 Million asset sale http://finance.yahoo.com/news/Samson-Oil...
After transaction and recent share issue completed, SSN will have 80 MM shares, $80 million cash, and Bakken and Niobrara assets.
SSN is a no brainer 200% 300% gainer.
SSN:AMEX $.73 sells oil assets for $70 Million
On Thursday SSN announced oil shale asset sale for $70 Million.
After transaction and recent share issue completed, SSN will have 80 MM shares, $80 million cash, and Bakken and Niobrara assets.
SSN is a no brainer 200% - 300% gainer.
http://finance.yahoo.com/news/Samson-Oil-Gas-Agrees-to-Sell-bw-3631467802.html?x=0
SSN ($.73) sells oil assets for $70 Million
On Thursday SSN announced oil shale asset sale for $70 Million.
After transaction and recent share issue completed, SSN will have 80 MM shares, $80 million cash, and Bakken and Niobrara assets.
SSN is a no brainer 200% - 300% gainer.
http://finance.yahoo.com/news/Samson-Oil-Gas-Agrees-to-Sell-bw-3631467802.html?x=0
SSN:AMEX $.73 sells oil assets for $70 Million
On Thursday SSN announced oil shale asset sale for $70 Million.
After transaction and recent share issue completed, SSN will have 80 MM shares, $80 million cash, and Bakken and Niobrara assets.
SSN is a no brainer 200% - 300% gainer.
http://finance.yahoo.com/news/Samson-Oil-Gas-Agrees-to-Sell-bw-3631467802.html?x=0
NMTI:NASDAQ green, double bottom in. Going to explode to $1 ++
http://finance.yahoo.com/echarts?s=NMTI+Interactive#symbol=NMTI;range=5d
NMTI declined 400% last week, an absurd overreaction to PRELIMINARY results that were OVERALL POSITIVE:
-STARFlex provided SMALL BENEFIT OVER CURRENT BEST MEDICAL THERAPY and maintained an excellent safety profile. NMTI is discussing next steps with the FDA.
Other useful DD and links:
-NMTI dramatically oversold:
http://messages.finance.yahoo.com/Stocks...
-55% of float owned by institutions. "Available float" only 7 million shares.
-Insiders have purchased over 800,000 shares at prices over $2 in last 6 months.
-The most successful U.S. hedge fund- Renaissance Technololgies, owns NMTI. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
-In may, the NMTI RT2 Delivery System was lauched in France and will be launched all throughout Europe over the next few months.
http://finance.yahoo.com/news/NMT-Medica...
-NMTI Owns or licenses 136 patents, relating to structural heart repair implant technologies and other related cardiovascular implant technologies.
NMTI:NASDAQ green, double bottom in. Going to explode to $1 ++
http://finance.yahoo.com/echarts?s=NMTI+Interactive#symbol=NMTI;range=5d
NMTI declined 400% last week, an absurd overreaction to PRELIMINARY results that were OVERALL POSITIVE:
-STARFlex provided SMALL BENEFIT OVER CURRENT BEST MEDICAL THERAPY and maintained an excellent safety profile. NMTI is discussing next steps with the FDA.
Other useful DD and links:
-NMTI dramatically oversold:
http://messages.finance.yahoo.com/Stocks...
-55% of float owned by institutions. "Available float" only 7 million shares.
-Insiders have purchased over 800,000 shares at prices over $2 in last 6 months.
-The most successful U.S. hedge fund- Renaissance Technololgies, owns NMTI. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
-In may, the NMTI RT2 Delivery System was lauched in France and will be launched all throughout Europe over the next few months.
http://finance.yahoo.com/news/NMT-Medica...
-NMTI Owns or licenses 136 patents, relating to structural heart repair implant technologies and other related cardiovascular implant technologies.
NMTI green, double bottom in. Going to explode to $1 ++
http://finance.yahoo.com/echarts?s=NMTI+Interactive#symbol=NMTI;range=5d
NMTI declined 400% last week, an absurd overreaction to PRELIMINARY results that were OVERALL POSITIVE:
-STARFlex provided SMALL BENEFIT OVER CURRENT BEST MEDICAL THERAPY and maintained an excellent safety profile. NMTI is discussing next steps with the FDA.
Other useful DD and links:
-NMTI dramatically oversold:
http://messages.finance.yahoo.com/Stocks...
-55% of float owned by institutions. "Available float" only 7 million shares.
-Insiders have purchased over 800,000 shares at prices over $2 in last 6 months.
-The most successful U.S. hedge fund- Renaissance Technololgies, owns NMTI. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
-In may, the NMTI RT2 Delivery System was lauched in France and will be launched all throughout Europe over the next few months.
http://finance.yahoo.com/news/NMT-Medica...
-NMTI Owns or licenses 136 patents, relating to structural heart repair implant technologies and other related cardiovascular implant technologies.
NMTI DD posts: Short term double:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=51476653
NMTI DD Posts: Straight back to $1.50
http://seekingalpha.com/instablog/399559-chemistfrog/77299-nmt-medical-incorporated-is-dramatically-oversold-after-closure-trial-data
Shares of NMT Medical, Inc. (NASDAQ: NMTI), a medical device company that designs, develops, manufactures and markets proprietary implants that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures were dramatically oversold after its CLOSURE I using the STARFlex technology failed to meet its primary endpoint. The trial data failed to show superiority to current medical therapy for preventing recurrent strokes and TIAs. This may or may not be the end of the line for the STARFlex technology at least for the CLOSURE I application. However, there is much more to this company than this one device.
Most importantly is the CE Mark it has already earned in Europe for its CardioSEAL technology in 1996. The CardioSEAL is a catheter delivered cardiac implant device designed to close holes in the heart. In 2002, they received premarket approval (PMA) from the U.S. Food and Drug Administration allowing commercial sale of the company's CardioSEAL cardiac septal repair implant in the United States for patients with ventricular septal defects (VSD) that are not candidates for surgical closure. NMT Medical has already gotten its foot in the door in Europe and at least their toes in the door in the United States so their future, it appears, is not dependent on the CLOSURE I product that has a lot of questions to be answered about it before it can continue.
Additionally, please note the closing comment CEO Frank Martin made today when announcing the trial data results: "We are continuing to develop the next generation of bioabsorbable implants, including our BioTREK™ device. In addition, we should note that the results of CLOSURE I have no impact on the status of our current FDA and CE Mark approvals for ventricular septal defect (VSD) and atrial level shunt patients.”
Please view the 52-week chart as well as the 5-year chart on NMTI, and you will note that the stock is now trading well below most points except in parts of 2008. The selloff on June 18th was way overdone, and the price should recorrect back to the $1 range over the next few weeks, if not days.
Additonal information on their STARFlex, CardioSEAL as well as their BioSTAR technologies can be viewed on their website at http://www.nmtmedical.com/technology.asp... Remember to do your own DD before purchasing any stocks and note that I have a long position in NMTI. Good luck and please utilize NMTI as a long-term investment and not only a short-term trade. There should and will be many other clinical trial results and approvals coming out of NMT Medical, and I will be anxiously awaiting all of them. Heart disease is a leading killer worldwide, and NMT Medical is equiping the medical device field with good options
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_N/threadview?m=tm&bn=12693&tid=10598&mid=10598&tof=1&frt=2
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_N/threadview?m=tm&bn=12693&tid=10929&mid=10929&tof=12&frt=2
FSII will be $6 after earnings IMO. The offering will give them the working capital to ramp up production to a much higher level.
This is going to be a hedge fund and market darling hang on and enjoy the ride.
I also love INTT, same sector, $3.6, 8 MM float:
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=9630&tid=2769&mid=2769&tof=1&frt=2
CHP $1.50 Tomorrow. BULLISH Guidance. PROFITABLE next quarter based on guidance: $90 MM++ quarterly run rate, 16% margin = $4 Million EBITDA, $1 million quarterly profit.
Also Asia growing at double digits.
"Importantly, we exited the quarter with revenues once again exceeding $30 million per month, with gross margins expanding to approximately 16 percent for April, and with a much improved backlog over the prior quarter
CHP Your joking, right? Just had a credit amendment, Bullish Seekinh Alpha article out tonight, CHP is better than 90% of the dogs posted here.
CHP:NYSE $1.06 huge move possible Tuesday on earnings
CHP could move on earnings pre market Tuesday. The last earnings PR in April was very bullish on outlook, with backlog, sales and margins increasing. With the small float, this could go north of $2 in a hurry if the Tuesday earnings report is in line.
Also like the fact that the best small cap hdege fund in the world, Renaissance, owns a stake.
CHP:NYSE $1.06 huge move possible Tuesday on earnings
CHP could move on earnings pre market Tuesday. The last earnings PR in April was very bullish on outlook, with backlog, sales and margins increasing. With the small float, this could go north of $2 in a hurry if the Tuesday earnings report is in line.
Also like the fact that the best small cap hdege fund in the world, Renaissance, owns a stake.
INTT exploding 3 Forward PE ratio NASDAQ's best value
INTT has reached 52 week highs but is still trading at a huge discount to peers in the semconductor test sector. $14 MILLION SALES AND $.30 EPS FOR Q2 2010 ARE REALISTIC PROJECTIONS. These results are far stronger than when INTT traded for $8 in 2005.
http://seekingalpha.com/article/204613-intest-chairman-sends-buy-signal-with-sell-order
-The semiconductor testsector is BOOMING driven by computer upgrades induced by Windows 7. LTXC, TER, and AMKR have posted the best results in years, and have risen 500%.
-INTT just announced $.14 EPS for Q1 2010. Q1 bookings increased 30% to $14 million.
-INTT trades at a P/S ratio of 0.6 compared to the Industry average of 2.4 If INTT traded at even HALF the sector average it would be $7.
-The most successful U.S. hedge fund- Renaissance Technololgies, owns INTT. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
-INTT has slashed costs to the bone by rationalizing facilities.
-INTT has a tightly held 8 Million float that is 38% instituitional owned.
-In short, INTT has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 8 MM share float
- 35 MM market cap
- $50 MM + revenues
- Last PR: $.14 EPS and Healthy increase in backlog.
- Last PR: Revenues and net income will be go up this quarter. Profitable again.
- Last CC: Customers, new and old, expected to ramp up production in 2010.
- Traded at $8+ in 2005
- Major players in sector (AMKR LTXC TER) have gained up to 500% in 2009 while INTT is still under the radar.
- Frequently mentioned as acquisition candidate because of heavy industry consolidation.
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.
INTT exploding 3 Forward PE ratio NASDAQ's best value
INTT has reached 52 week highs but is still trading at a huge discount to peers in the semconductor test sector. $14 MILLION SALES AND $.30 EPS FOR Q2 2010 ARE REALISTIC PROJECTIONS. These results are far stronger than when INTT traded for $8 in 2005.
http://seekingalpha.com/article/204613-intest-chairman-sends-buy-signal-with-sell-order
-The semiconductor testsector is BOOMING driven by computer upgrades induced by Windows 7. LTXC, TER, and AMKR have posted the best results in years, and have risen 500%.
-INTT just announced $.14 EPS for Q1 2010. Q1 bookings increased 30% to $14 million.
-INTT trades at a P/S ratio of 0.6 compared to the Industry average of 2.4 If INTT traded at even HALF the sector average it would be $7.
-The most successful U.S. hedge fund- Renaissance Technololgies, owns INTT. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
-INTT has slashed costs to the bone by rationalizing facilities.
-INTT has a tightly held 8 Million float that is 38% instituitional owned.
-In short, INTT has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 8 MM share float
- 35 MM market cap
- $50 MM + revenues
- Last PR: $.14 EPS and Healthy increase in backlog.
- Last PR: Revenues and net income will be go up this quarter. Profitable again.
- Last CC: Customers, new and old, expected to ramp up production in 2010.
- Traded at $8+ in 2005
- Major players in sector (AMKR LTXC TER) have gained up to 500% in 2009 while INTT is still under the radar.
- Frequently mentioned as acquisition candidate because of heavy industry consolidation.
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.
FSII sold too early but had 125000 shares can't complain.
FSII $.20 EPS for Q3!! $4 ++ tomorrow Revised Third Quarter Guidance
Given the quarter-to-date orders, the company now expects third quarter orders to be between $28 and $30 million, as compared to $22.8 million in the second quarter of fiscal 2010.* Based on quarter-to-date shipments, the company now expects third quarter fiscal 2010 revenues of $27 to $29 million as compared to $18.9 million in the second quarter of fiscal 2010.* Assuming that the company can achieve anticipated gross profit margin and the operating expense levels, the company expects net income of $5.0 to $6.0 million for the third quarter of fiscal 2010, as compared to $609,000 in the second quarter of fiscal 2010.*
FSII $.20 EPS for Q3!! $4 ++ tomorrow Revised Third Quarter Guidance
Given the quarter-to-date orders, the company now expects third quarter orders to be between $28 and $30 million, as compared to $22.8 million in the second quarter of fiscal 2010.* Based on quarter-to-date shipments, the company now expects third quarter fiscal 2010 revenues of $27 to $29 million as compared to $18.9 million in the second quarter of fiscal 2010.* Assuming that the company can achieve anticipated gross profit margin and the operating expense levels, the company expects net income of $5.0 to $6.0 million for the third quarter of fiscal 2010, as compared to $609,000 in the second quarter of fiscal 2010.*
AGEN $1.38 DNDN like results Thursday
German conference Thursday results are 3 x better than DNDN.
$2 + Thursdayhttp://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=tm&bn=538&tid=64870&mid=64870&tof=2&frt=1
AGEN $1.38 DNDN like results Thursday
German conference Thursday results are 3 x better than DNDN.
$2 + Thursdayhttp://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=tm&bn=538&tid=64870&mid=64870&tof=2&frt=1
May 20 presentation: AGEN Cancer Vaccine 3 X better than DNDN
http://www.chasingthealpha.com/2010/05/agen-some-undiscovered-news-about-data.html
AGEN will release a PR this week on May 20 presentation. The results are amazing.
Results: HSp vaccine was well tolerated with no serious adverse events attributable to vaccine and no related grade 3 or 4 toxicities. In patients with recurrent GBM (n=32) the overall median survival approximated 44 weeks post-resection and the majority (94%) of patients survived beyond the historical median of 26-weeks.
****Approximately 70% of patients survived beyond 36 weeks and 41% survived up to or longer than 1-year.*****
All patients with immunological endpoints tested to date exhibited a significant innate immune response following vaccine administration and 92% of patients demonstrated CD8 T cell IFN gamma production upon restimulation with recombinant gp-96 (p<0.01). The majority of patients (92%) exhibited significant Th1 type responses as measured by multi-cytokine qpCR. The presence of an adaptive immune response and minimal residual disease was associated with survival beyond 36 weeks. In patients with newly diagnosed GBM (n=8; trial initiated 2009), there have been no significant toxicities associated with concurrent treatment of HSppC-96 and temozolomide. Clinical and immunologic evaluation is ongoing.
In contrast with DNDN and Provenge only increased survival by only 23% for prostate cancer. This is a huge victory for AGEN and shareholders. Historically, recurrent glioblastoma multiforme has a median survival of three to six months. 70% INCREASE IN SURVIVAL.
RPC gonna skyrocket this week on India marketing meetings. Good Yahoo DD Post:
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_R/threadview?m=tm&bn=351&tid=22544&mid=22544&tof=1&frt=2
AGEN $1.1 + $.16 DNDN like results
AGEN has a cancer vaccine called Oncophage. Results blow DNDN away. Oncophage increased survival by 70%. Provenge increased survival by only 23%. Results to be presented May 20 easy 50% gain IMO
Conference website:
http://www.braintumor2010.de/call.html
Introduction: Autologous heat shock protein vaccine HSPP C-96 (Oncophage®) is derived from a patient’s
individual tumor and contains glycoprotein-96 (gp96) polypeptide associated with cancer-specific antigenic
peptides. HSPP C-96 has been shown to elicit innate and adaptive immune response in patients with recurrent
glioma. In ongoing investigations, we evaluated the use of HSPP C-96 for treatment of Recurrent Glioblastoma
Multiforme (GBM) and in combination with chemotherapy in patients with Newly Diagnosed GBM.
Materials and Methods:Two ongoing, phase 2, open-labeled investigations designed to evaluate clinical
efficacy and immunologic response of HSPP C-96 treatment in patients with recurrent GBM (multi-center
investigation) and newly diagnosed GBM (single-center investigation). Patients with recurrent GBM receive
HSPP C-96 treatment within 5 weeks post-surgery and patients with newly diagnosed GBM are treated with
concurrent HSPP C-96 and temozolomide following surgery and standard of care radiation and temozolomide
therapy.
Results: HSP vaccine was well tolerated with no serious adverse events attributable to vaccine and no related
grade 3 or 4 toxicities. In patients with recurrent GBM (n=32) the overall median survival approximated 44
weeks post-resection and the majority (94%) of patients survived beyond the historical median of 26-weeks.
Approximately 70% of patients survived beyond 36 weeks and 41% survived up to or longer than 1-year. All patients
with immunological endpoints tested to date exhibited a significant innate immune response following
vaccine administration and 92% of patients demonstrated CD8 T cell IFN gamma production upon restimulation with recombinant gp-96 (p<0.01). The majority of patients (92%) exhibited significant Th1 type responses
as measured by multi-cytokine qPCR. The presence of an adaptive immune response and minimal residual
disease was associated with survival beyond 36 weeks. In patients with newly diagnosed GBM (n=8; trial
initiated 2009), there have been no significant toxicities associated with concurrent treatment of HSPP C-96
and temozolomide. Clinical and immunologic evaluation is ongoing.
Conclusions: HSPP C-96 is safe for patients with recurrent glioma and appear to be safe with concurrent
treatment with chemotherapy. HSPP C-96 evokes a specific and innate immune response in patients with
recurrent glioma and survival data available to date indicates HSPP C-96 vaccine provides a possible clinical
benefit with a favorable safety profile.
Introduction: Autologous heat shock protein vaccine HSPP C-96 (Oncophage®) is derived from a patient’s
individual tumor and contains glycoprotein-96 (gp96) polypeptide associated with cancer-specific antigenic
peptides. HSPP C-96 has been shown to elicit innate and adaptive immune response in patients with recurrent
glioma. In ongoing investigations, we evaluated the use of HSPP C-96 for treatment of Recurrent Glioblastoma
Multiforme (GBM) and in combination with chemotherapy in patients with Newly Diagnosed GBM.
Materials and Methods:Two ongoing, phase 2, open-labeled investigations designed to evaluate clinical
efficacy and immunologic response of HSPP C-96 treatment in patients with recurrent GBM (multi-center
investigation) and newly diagnosed GBM (single-center investigation). Patients with recurrent GBM receive
HSPP C-96 treatment within 5 weeks post-surgery and patients with newly diagnosed GBM are treated with
concurrent HSPP C-96 and temozolomide following surgery and standard of care radiation and temozolomide
therapy.
Results: HSP vaccine was well tolerated with no serious adverse events attributable to vaccine and no related
grade 3 or 4 toxicities. In patients with recurrent GBM (n=32) the overall median survival approximated 44
weeks post-resection and the majority (94%) of patients survived beyond the historical median of 26-weeks.
Approximately 70% of patients survived beyond 36 weeks and 41% survived up to or longer than 1-year. All patients
with immunological endpoints tested to date exhibited a significant innate immune response following
vaccine administration and 92% of patients demonstrated CD8 T cell IFN gamma production upon restimulation with recombinant gp-96 (p<0.01). The majority of patients (92%) exhibited significant Th1 type responses
as measured by multi-cytokine qPCR. The presence of an adaptive immune response and minimal residual
disease was associated with survival beyond 36 weeks. In patients with newly diagnosed GBM (n=8; trial
initiated 2009), there have been no significant toxicities associated with concurrent treatment of HSPP C-96
and temozolomide. Clinical and immunologic evaluation is ongoing.
Conclusions: HSPP C-96 is safe for patients with recurrent glioma and appear to be safe with concurrent
treatment with chemotherapy. HSPP C-96 evokes a specific and innate immune response in patients with
recurrent glioma and survival data available to date indicates HSPP C-96 vaccine provides a possible clinical
benefit with a favorable safety profile.
AGEN $1.1 + $.16 DNDN like results
AGEN has a cancer vaccine called Oncophage. Results blow DNDN away. Oncophage increased survival by 70%. Provenge increased survival by only 23%. Results to be presented May 20 easy 50% gain IMO
Conference website:
http://www.braintumor2010.de/call.html
Introduction: Autologous heat shock protein vaccine HSPP C-96 (Oncophage®) is derived from a patient’s
individual tumor and contains glycoprotein-96 (gp96) polypeptide associated with cancer-specific antigenic
peptides. HSPP C-96 has been shown to elicit innate and adaptive immune response in patients with recurrent
glioma. In ongoing investigations, we evaluated the use of HSPP C-96 for treatment of Recurrent Glioblastoma
Multiforme (GBM) and in combination with chemotherapy in patients with Newly Diagnosed GBM.
Materials and Methods:Two ongoing, phase 2, open-labeled investigations designed to evaluate clinical
efficacy and immunologic response of HSPP C-96 treatment in patients with recurrent GBM (multi-center
investigation) and newly diagnosed GBM (single-center investigation). Patients with recurrent GBM receive
HSPP C-96 treatment within 5 weeks post-surgery and patients with newly diagnosed GBM are treated with
concurrent HSPP C-96 and temozolomide following surgery and standard of care radiation and temozolomide
therapy.
Results: HSP vaccine was well tolerated with no serious adverse events attributable to vaccine and no related
grade 3 or 4 toxicities. In patients with recurrent GBM (n=32) the overall median survival approximated 44
weeks post-resection and the majority (94%) of patients survived beyond the historical median of 26-weeks.
Approximately 70% of patients survived beyond 36 weeks and 41% survived up to or longer than 1-year. All patients
with immunological endpoints tested to date exhibited a significant innate immune response following
vaccine administration and 92% of patients demonstrated CD8 T cell IFN gamma production upon restimulation with recombinant gp-96 (p<0.01). The majority of patients (92%) exhibited significant Th1 type responses
as measured by multi-cytokine qPCR. The presence of an adaptive immune response and minimal residual
disease was associated with survival beyond 36 weeks. In patients with newly diagnosed GBM (n=8; trial
initiated 2009), there have been no significant toxicities associated with concurrent treatment of HSPP C-96
and temozolomide. Clinical and immunologic evaluation is ongoing.
Conclusions: HSPP C-96 is safe for patients with recurrent glioma and appear to be safe with concurrent
treatment with chemotherapy. HSPP C-96 evokes a specific and innate immune response in patients with
recurrent glioma and survival data available to date indicates HSPP C-96 vaccine provides a possible clinical
benefit with a favorable safety profile.
Introduction: Autologous heat shock protein vaccine HSPP C-96 (Oncophage®) is derived from a patient’s
individual tumor and contains glycoprotein-96 (gp96) polypeptide associated with cancer-specific antigenic
peptides. HSPP C-96 has been shown to elicit innate and adaptive immune response in patients with recurrent
glioma. In ongoing investigations, we evaluated the use of HSPP C-96 for treatment of Recurrent Glioblastoma
Multiforme (GBM) and in combination with chemotherapy in patients with Newly Diagnosed GBM.
Materials and Methods:Two ongoing, phase 2, open-labeled investigations designed to evaluate clinical
efficacy and immunologic response of HSPP C-96 treatment in patients with recurrent GBM (multi-center
investigation) and newly diagnosed GBM (single-center investigation). Patients with recurrent GBM receive
HSPP C-96 treatment within 5 weeks post-surgery and patients with newly diagnosed GBM are treated with
concurrent HSPP C-96 and temozolomide following surgery and standard of care radiation and temozolomide
therapy.
Results: HSP vaccine was well tolerated with no serious adverse events attributable to vaccine and no related
grade 3 or 4 toxicities. In patients with recurrent GBM (n=32) the overall median survival approximated 44
weeks post-resection and the majority (94%) of patients survived beyond the historical median of 26-weeks.
Approximately 70% of patients survived beyond 36 weeks and 41% survived up to or longer than 1-year. All patients
with immunological endpoints tested to date exhibited a significant innate immune response following
vaccine administration and 92% of patients demonstrated CD8 T cell IFN gamma production upon restimulation with recombinant gp-96 (p<0.01). The majority of patients (92%) exhibited significant Th1 type responses
as measured by multi-cytokine qPCR. The presence of an adaptive immune response and minimal residual
disease was associated with survival beyond 36 weeks. In patients with newly diagnosed GBM (n=8; trial
initiated 2009), there have been no significant toxicities associated with concurrent treatment of HSPP C-96
and temozolomide. Clinical and immunologic evaluation is ongoing.
Conclusions: HSPP C-96 is safe for patients with recurrent glioma and appear to be safe with concurrent
treatment with chemotherapy. HSPP C-96 evokes a specific and innate immune response in patients with
recurrent glioma and survival data available to date indicates HSPP C-96 vaccine provides a possible clinical
benefit with a favorable safety profile.
AGEN $1.1 + $.16 DNDN like results
AGEN has a cancer vaccine called Oncophage. Results blow DNDN away. Oncophage increased survival by 70%. Provenge increased survival by only 23%. Results to be presented May 20 easy 50% gain IMO
Conference website:
http://www.braintumor2010.de/call.html
Introduction: Autologous heat shock protein vaccine HSPP C-96 (Oncophage®) is derived from a patient’s
individual tumor and contains glycoprotein-96 (gp96) polypeptide associated with cancer-specific antigenic
peptides. HSPP C-96 has been shown to elicit innate and adaptive immune response in patients with recurrent
glioma. In ongoing investigations, we evaluated the use of HSPP C-96 for treatment of Recurrent Glioblastoma
Multiforme (GBM) and in combination with chemotherapy in patients with Newly Diagnosed GBM.
Materials and Methods:Two ongoing, phase 2, open-labeled investigations designed to evaluate clinical
efficacy and immunologic response of HSPP C-96 treatment in patients with recurrent GBM (multi-center
investigation) and newly diagnosed GBM (single-center investigation). Patients with recurrent GBM receive
HSPP C-96 treatment within 5 weeks post-surgery and patients with newly diagnosed GBM are treated with
concurrent HSPP C-96 and temozolomide following surgery and standard of care radiation and temozolomide
therapy.
Results: HSP vaccine was well tolerated with no serious adverse events attributable to vaccine and no related
grade 3 or 4 toxicities. In patients with recurrent GBM (n=32) the overall median survival approximated 44
weeks post-resection and the majority (94%) of patients survived beyond the historical median of 26-weeks.
Approximately 70% of patients survived beyond 36 weeks and 41% survived up to or longer than 1-year. All patients
with immunological endpoints tested to date exhibited a significant innate immune response following
vaccine administration and 92% of patients demonstrated CD8 T cell IFN gamma production upon restimulation with recombinant gp-96 (p<0.01). The majority of patients (92%) exhibited significant Th1 type responses
as measured by multi-cytokine qPCR. The presence of an adaptive immune response and minimal residual
disease was associated with survival beyond 36 weeks. In patients with newly diagnosed GBM (n=8; trial
initiated 2009), there have been no significant toxicities associated with concurrent treatment of HSPP C-96
and temozolomide. Clinical and immunologic evaluation is ongoing.
Conclusions: HSPP C-96 is safe for patients with recurrent glioma and appear to be safe with concurrent
treatment with chemotherapy. HSPP C-96 evokes a specific and innate immune response in patients with
recurrent glioma and survival data available to date indicates HSPP C-96 vaccine provides a possible clinical
benefit with a favorable safety profile.
Introduction: Autologous heat shock protein vaccine HSPP C-96 (Oncophage®) is derived from a patient’s
individual tumor and contains glycoprotein-96 (gp96) polypeptide associated with cancer-specific antigenic
peptides. HSPP C-96 has been shown to elicit innate and adaptive immune response in patients with recurrent
glioma. In ongoing investigations, we evaluated the use of HSPP C-96 for treatment of Recurrent Glioblastoma
Multiforme (GBM) and in combination with chemotherapy in patients with Newly Diagnosed GBM.
Materials and Methods:Two ongoing, phase 2, open-labeled investigations designed to evaluate clinical
efficacy and immunologic response of HSPP C-96 treatment in patients with recurrent GBM (multi-center
investigation) and newly diagnosed GBM (single-center investigation). Patients with recurrent GBM receive
HSPP C-96 treatment within 5 weeks post-surgery and patients with newly diagnosed GBM are treated with
concurrent HSPP C-96 and temozolomide following surgery and standard of care radiation and temozolomide
therapy.
Results: HSP vaccine was well tolerated with no serious adverse events attributable to vaccine and no related
grade 3 or 4 toxicities. In patients with recurrent GBM (n=32) the overall median survival approximated 44
weeks post-resection and the majority (94%) of patients survived beyond the historical median of 26-weeks.
Approximately 70% of patients survived beyond 36 weeks and 41% survived up to or longer than 1-year. All patients
with immunological endpoints tested to date exhibited a significant innate immune response following
vaccine administration and 92% of patients demonstrated CD8 T cell IFN gamma production upon restimulation with recombinant gp-96 (p<0.01). The majority of patients (92%) exhibited significant Th1 type responses
as measured by multi-cytokine qPCR. The presence of an adaptive immune response and minimal residual
disease was associated with survival beyond 36 weeks. In patients with newly diagnosed GBM (n=8; trial
initiated 2009), there have been no significant toxicities associated with concurrent treatment of HSPP C-96
and temozolomide. Clinical and immunologic evaluation is ongoing.
Conclusions: HSPP C-96 is safe for patients with recurrent glioma and appear to be safe with concurrent
treatment with chemotherapy. HSPP C-96 evokes a specific and innate immune response in patients with
recurrent glioma and survival data available to date indicates HSPP C-96 vaccine provides a possible clinical
benefit with a favorable safety profile.
INTT 3 forward PE hot sector
INTT has reached 52 week highs but is still trading at a huge discount to peers in the semconductor test sector.
-The sector is BOOMING driven by computer upgrades induced by Windows 7. LTXC, TER, and AMKR have posted the best results in years, and have risen 500%.
-INTT just pre- announced $.14 EPS for Q1 2010. Q1 bookings increased 30% to $14 million.
-Since sales have been strongly correlated with prior quarter bookings, $14 MILLION SALES AND $.25 EPS FOR Q2 2010 ARE REALISTIC PROJECTIONS. These results are far stronger than when INTT traded for $8 in 2005.
-INTT trades at a P/S ratio of 0.6 compared to the Industry average of 2.4 If INTT traded at even HALF the sector average it would be $7.
-The most successful U.S. hedge fund- Renaissance Technololgies, owns INTT. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
-INTT has slashed costs to the bone by rationalizing facilities.
-INTT has a tightly held 8 Million float that is 38% instituitional owned.
-In short, INTT has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 8 MM share float
- 35 MM market cap
- $50 MM + revenues
- Last PR: $.14 EPS and Healthy increase in backlog.
- Last PR: Revenues and net income will be go up this quarter. Profitable again.
- Last CC: Customers, new and old, expected to ramp up production in 2010.
- Traded at $8+ in 2005
- Major players in sector (AMKR LTXC TER) have gained up to 500% in 2009 while INTT is still under the radar.
- Frequently mentioned as acquisition candidate because of heavy industry consolidation.
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.
INTT 3 forward PE hot sector
INTT has reached 52 week highs but is still trading at a huge discount to peers in the semconductor test sector.
-The sector is BOOMING driven by computer upgrades induced by Windows 7. LTXC, TER, and AMKR have posted the best results in years, and have risen 500%.
-INTT just pre- announced $.14 EPS for Q1 2010. Q1 bookings increased 30% to $14 million.
-Since sales have been strongly correlated with prior quarter bookings, $14 MILLION SALES AND $.25 EPS FOR Q2 2010 ARE REALISTIC PROJECTIONS. These results are far stronger than when INTT traded for $8 in 2005.
-INTT trades at a P/S ratio of 0.6 compared to the Industry average of 2.4 If INTT traded at even HALF the sector average it would be $7.
-The most successful U.S. hedge fund- Renaissance Technololgies, owns INTT. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
-INTT has slashed costs to the bone by rationalizing facilities.
-INTT has a tightly held 8 Million float that is 38% instituitional owned.
-In short, INTT has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 8 MM share float
- 35 MM market cap
- $50 MM + revenues
- Last PR: $.14 EPS and Healthy increase in backlog.
- Last PR: Revenues and net income will be go up this quarter. Profitable again.
- Last CC: Customers, new and old, expected to ramp up production in 2010.
- Traded at $8+ in 2005
- Major players in sector (AMKR LTXC TER) have gained up to 500% in 2009 while INTT is still under the radar.
- Frequently mentioned as acquisition candidate because of heavy industry consolidation.
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.
INTT 3 forward PE hot sector
INTT has reached 52 week highs but is still trading at a huge discount to peers in the semconductor test sector.
-The sector is BOOMING driven by computer upgrades induced by Windows 7. LTXC, TER, and AMKR have posted the best results in years, and have risen 500%.
-INTT just pre- announced $.14 EPS for Q1 2010. Q1 bookings increased 30% to $14 million.
-Since sales have been strongly correlated with prior quarter bookings, $14 MILLION SALES AND $.25 EPS FOR Q2 2010 ARE REALISTIC PROJECTIONS. These results are far stronger than when INTT traded for $8 in 2005.
-INTT trades at a P/S ratio of 0.6 compared to the Industry average of 2.4 If INTT traded at even HALF the sector average it would be $7.
-The most successful U.S. hedge fund- Renaissance Technololgies, owns INTT. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.
-INTT has slashed costs to the bone by rationalizing facilities.
-INTT has a tightly held 8 Million float that is 38% instituitional owned.
-In short, INTT has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 8 MM share float
- 35 MM market cap
- $50 MM + revenues
- Last PR: $.14 EPS and Healthy increase in backlog.
- Last PR: Revenues and net income will be go up this quarter. Profitable again.
- Last CC: Customers, new and old, expected to ramp up production in 2010.
- Traded at $8+ in 2005
- Major players in sector (AMKR LTXC TER) have gained up to 500% in 2009 while INTT is still under the radar.
- Frequently mentioned as acquisition candidate because of heavy industry consolidation.
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.
CTHR Huge news after hours $3 tomorrow
http://finance.yahoo.com/news/Charles-Colvard-Signs-New-bw-781867952.html?x=0
This was a $20 stock a few years ago. Artifical diamonds a huge market.
CTHR Huge news after hours $3 tomorrow
http://finance.yahoo.com/news/Charles-Colvard-Signs-New-bw-781867952.html?x=0
This was a $20 stock a few years ago. Artifical diamonds a huge market.